Sibylle Loibl

Research interests

Publications

• Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2214131

• Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · https://doi.org/10.1016/j.annonc.2023.11.016

• ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2021.09.019

• Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2105215

• Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

  Journal of Clinical Oncology · 2021 · 10.1200/jco.20.03399

• Breast cancer

  The Lancet · 2021 · 10.1016/s0140-6736(20)32381-3

• Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2028485

• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

  The Lancet · 2020 · 10.1016/s0140-6736(20)32531-9

• Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1914609

• Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1813904

• Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1814017

• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

  New England Journal of Medicine · 2018 · 10.1056/nejmoa1810527

• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

  Advances in Anatomic Pathology · 2017 · 10.1097/pap.0000000000000161

• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

  Annals of Oncology · 2017 · 10.1093/annonc/mdx308

• Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30777-5

• Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

  Advances in Anatomic Pathology · 2017 · 10.1097/pap.0000000000000162

• Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30904-x

• HER2-positive breast cancer

  The Lancet · 2016 · 10.1016/s0140-6736(16)32417-5

• Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1505270

• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

  Annals of Oncology · 2014 · 10.1093/annonc/mdu112

• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

  The Lancet · 2014 · https://doi.org/10.1016/s0140-6736(13)62422-8

• Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70160-3

• Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers

  Journal of Clinical Oncology · 2014 · 10.1200/jco.2014.58.1967

• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014

  Annals of Oncology · 2014 · https://doi.org/10.1093/annonc/mdu450

• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt303

• Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2011.38.8595

• Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.23.7370

Current projects

No projects listed.